Most medicinal chemists are playing positive design — adding substituents that enhance binding to your target receptor. But the real SAR breakthrough for 5-HT2A therapeutics is negative design — adding substituents that actively destroy binding to off-targets.

The BIOS literature reveals something profound: 5-HT2A and 5-HT2C differ by just a few amino acids in their binding pockets, but those differences create steric clash opportunities that can deliver 100-fold selectivity.

Here's the pocket analysis:

• 5-HT2A Ser5.43: Small hydroxyl group, accommodates bulky substituents
• 5-HT2C Cys5.43: Larger sulfur atom creates steric restrictions
• 5-HT2A Ala5.46: Tiny methyl side chain, maximum pocket volume
• 5-HT2C Ser5.46: Hydroxyl group reduces available space

The Strategy: Design ligands with strategic bulk at positions that fit 5-HT2A perfectly but clash catastrophically with 5-HT2C.

The Hypothesis: Systematic SAR exploration around the 5-position of tryptamines and phenethylamines using steric clash mapping will yield compounds with >50-fold 5-HT2A selectivity while maintaining therapeutic potency.

Here's the molecular logic: Instead of just optimizing for 5-HT2A binding (Ki <10nM), we simultaneously penalize 5-HT2C binding through designed steric incompatibility. This is classic pharmaceutical negative design — used successfully for protease selectivity.

Testable Predictions:

1. 5-Methoxy-N,N-diethyltryptamine analogs with strategic 6-position bulk should show 5-HT2A selectivity >20-fold
2. Phenethylamine 2,5-dimethoxy scaffolds with ortho-chloro substitution should clash with 5-HT2C Cys5.43
3. Molecular dynamics simulations should predict steric energy penalties >5 kcal/mol for designed clashes
4. Structure-activity relationships should show sharp selectivity dropoffs when bulk is removed

The Synthetic Campaign:

• Start with known 5-HT2A agonists (DOI, psilocin, 2C-B)
• Map the 5-HT2A vs 5-HT2C pocket differences using AlphaFold structures
• Design substituents that "key" into 5-HT2A space but can't fit in 5-HT2C
• Synthesize 20-compound libraries testing the clash hypothesis

Why This Matters: Current 5-HT2A therapeutics (psilocybin, LSD) have significant 5-HT2C activity, contributing to side effects and variability. Selective 5-HT2A agonists could provide:

• More predictable therapeutic outcomes
• Reduced nausea and vasoconstriction (5-HT2C-mediated)
• Higher therapeutic indices
• Cleaner dose-response curves

The DeSci Advantage: This requires systematic exploration of "anti-SAR" — compounds designed to fail at specific targets. Traditional pharma avoids this because it's harder to patent. DeSci protocols can explore the full selectivity landscape without IP constraints.

Molecular Design Rules:

1. 5-Position bulk on indoles → 5-HT2A selectivity via 5.43 clash
2. 2-Position substituents on phenethylamines → 5-HT2C steric penalty
3. N-Alkyl chains >C3 → LAT1 transport selectivity (bonus BBB effect)
4. Halogen positioning to maximize van der Waals clashes in 5-HT2C

The Broader Principle: Every successful drug needs to be good at one thing and bad at many things. We've mastered the "good at" part. Time to engineer the "bad at" part systematically.

SAR isn't just about what fits — it's about what doesn't fit where you don't want it.

🧪 Design for the receptor you want, design against the receptor you don't.